US stock · Healthcare sector · Diagnostics & Research
Company Logo

Agilent Technologies, Inc.

ANYSE

120.38

USD
-4.03
(-3.24%)
Market Closed
30.55P/E
24Forward P/E
1.18P/E to S&P500
35.994BMarket CAP
0.65%Div Yield
Upcoming Earnings
15 Aug-19 Aug
Shares Short
5/13/22
3.55M
Short % of Float
1.18%
Short % of Shares Outs.
1.18%
% Held by Insiders
0.25%
% Held by Institutions
90.96%
Beta
1.06
PEG Ratio
1.97
52w. high/low
179.57/112.64
Avg. Daily Volume
2.09M
Return %
Stock
S&P 500
1 year
(11.24)
(6.01)
3 years
74.49
39.24
5 years
102.73
63.25
Scale: |
High
Low
28.91
21.65
27.18
10.56
22.73
8.60
30.10
19.08
39.58
20.51
33.10
25.26
41.44
28.75
43.79
35.62
43.59
33.12
48.63
34.15
70.93
45.74
75.11
60.42
85.68
62.00
120.24
61.13
179.57
112.47
159.44
112.64
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
11.54
13.76
15.91
12.95
15.69
19.06
19.71
19.89
20.96
12.13
12.89
13.89
15.31
16.44
17.28
20.79
21.65
Earnings per share
7.67
1.62
1.91
(0.09)
1.97
2.92
3.31
2.12
1.51
1.20
1.42
2.12
0.98
3.41
2.33
3.98
4.19
FCF per share
1.04
2.07
1.66
0.81
1.72
3.09
2.97
2.81
1.52
1.18
2.01
2.21
2.83
2.75
2.60
4.26
4.24
Dividends per share
- -
- -
- -
- -
- -
- -
0.30
0.46
0.53
0.40
0.46
0.53
0.60
0.66
0.72
0.78
0.80
CAPEX per share
0.43
0.39
0.42
0.37
0.35
0.54
0.56
0.57
0.62
0.29
0.43
0.55
0.55
0.50
0.39
0.62
0.74
Book Value per sh.
7.50
6.49
6.90
9.33
12.41
14.93
15.19
15.54
12.51
12.74
14.82
14.18
14.79
15.52
17.44
16.95
17.09
Comm.Shares outs.
431
394
363
346
347
347
348
341
333
333
326
322
321
314
309
304
302
Avg. annual P/E ratio
3.2
15.8
11.3
(173.3)
11.7
10.3
8.6
15.7
26.8
32.8
30.4
27.9
68.4
21.9
39.6
36.2
30.5
P/E to S&P500
0.2
0.9
0.5
(2.4)
0.6
0.6
0.6
0.9
1.5
1.6
1.4
1.2
2.7
0.9
1.0
1.2
1.2
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
1.0%
1.4%
1.3%
1.0%
1.1%
0.9%
0.9%
0.9%
0.8%
0.5%
0.5%
Revenue (m)
4,973
5,420
5,774
4,481
5,444
6,615
6,858
6,782
6,981
4,038
4,202
4,472
4,914
5,163
5,339
6,319
6,527
Operating margin
9.3%
10.8%
13.8%
1.0%
10.4%
16.2%
16.3%
14.0%
11.9%
12.9%
14.6%
18.8%
18.9%
18.2%
15.8%
21.3%
22.5%
Depreciation (m)
170
191
201
162
202
253
301
372
384
253
246
212
210
238
308
321
250
Net profit (m)
3,307
638
693
(31)
684
1,012
1,153
724
504
401
462
684
316
1,071
719
1,210
1,263
Income tax rate
14.5%
4.8%
15.0%
542.9%
1.2%
1.9%
(10.5)%
15.7%
22.0%
8.8%
15.1%
14.8%
66.6%
(16.5)%
14.6%
11.0%
12.4%
Net profit margin
66.5%
11.8%
12.0%
(0.7)%
12.6%
15.3%
16.8%
10.7%
7.2%
9.9%
11.0%
15.3%
6.4%
20.7%
13.5%
19.1%
19.3%
Working capital (m)
2,008
1,883
2,838
3,086
3,732
2,736
3,381
3,798
2,710
2,690
2,906
2,677
1,109
1,948
2,091
1,890
1,830
Long-term debt (m)
2,087
2,125
2,904
2,190
1,932
2,112
2,699
2,762
1,655
1,912
1,801
1,799
1,791
2,284
2,729
2,730
2,730
Equity (m)
3,234
2,559
2,506
3,228
4,308
5,182
5,286
5,298
4,167
4,243
4,831
4,567
4,748
4,873
5,389
5,154
5,122
ROIC
49.3%
10.4%
10.7%
(6.4)%
10.8%
12.7%
13.9%
8.9%
9.1%
6.8%
7.3%
10.2%
4.6%
14.2%
8.7%
14.7%
15.3%
Return on capital
45.0%
9.0%
10.7%
1.0%
8.7%
10.6%
10.7%
8.9%
10.2%
6.5%
7.3%
10.3%
10.8%
10.3%
8.6%
14.0%
14.5%
Return on equity
102.3%
24.9%
27.7%
(1.0)%
15.9%
19.5%
21.8%
13.7%
12.1%
9.5%
9.6%
15.0%
6.7%
22.0%
13.3%
23.5%
24.7%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
91.0%
78.5%
65.1%
66.8%
67.5%
75.1%
39.6%
80.8%
69.1%
80.5%
80.1%
Div.&Repurch./FCF
821.4%
192.5%
131.2%
- -
18.8%
18.0%
17.0%
110.3%
74.3%
101.8%
89.3%
51.1%
67.4%
107.4%
78.7%
79.0%
88.4%
Capital Structure
30 Apr · 2022 | Q2
All numbers in millions
Total liabilities
$ 5,333
Total assets
$ 10,455
Long-term debt
$ 2,730
Cash and equiv.
$ 1,186
Goodwill
$ - -
Retained earnings
$ 160
Common stock
299
Enterprise Value
$ 37,538
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
1,599
1,575
1,158
Receivables
1,038
1,172
1,205
Inventory
720
830
879
Other
58
265
(96)
Current assets
3,415
3,799
3,474
Acc. Payable
354
446
475
Debt due
75
- -
- -
Other
1,038
1,262
1,109
Current liabilities
1,467
1,708
1,584
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
18.36%
9.18%
0.76%
Cash flow
61.60%
19.25%
8.39%
Earnings
68.29%
55.14%
21.75%
Dividends
6.31%
8.57%
10.98%
Book value
(4.36)%
3.21%
0.21%
Insider Trading
Type
Shares
Date
Mcdonnell Padraig
InKind
171
05/19/22
Raha Samraat S.
InKind
226
05/13/22
Thaysen Jacob
InKind
183
05/13/22
Ancher-Jensen Henrik
Award
5,598
05/03/22
Ancher-Jensen Henrik
Award
1,645
05/03/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
1,357
1,238
1,261
1,483
5,339
2021
1,548
1,525
1,586
1,660
6,319
2022
1,674
1,607
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.64
0.33
0.64
0.72
2.33
2021
0.95
0.71
0.87
1.45
3.98
2022
0.94
0.92
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.18
0.18
0.18
0.18
0.72
2021
0.19
0.19
0.19
0.19
0.78
2022
0.21
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Diagnostics & Research
CEO:
Mr. Michael McMullen
Full-time employees:
17,200
City:
Santa Clara
Address:
5301 Stevens Creek Blvd
IPO:
Nov 18, 1999
Website:
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Recent News
· 24 Nov, 2020 · The Wall Street Journal